Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

被引:199
作者
Meredith, Kenneth L. [1 ]
Weber, Jill M. [1 ]
Turaga, Kiran K. [1 ]
Siegel, Erin M. [2 ]
McLoughlin, Jim [3 ]
Hoffe, Sarah [4 ]
Marcovalerio, Melis [5 ]
Shah, Nilay [1 ]
Kelley, Scott [6 ]
Karl, Richard [1 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Prevent & Control, Tampa, FL USA
[3] Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA
[5] New York Presbyterian Vet Adm, Dept Surg, New York, NY USA
[6] Watson Clin, Dept Surg, Lakeland, FL USA
关键词
SQUAMOUS-CELL CARCINOMA; PREOPERATIVE CHEMORADIOTHERAPY; TRANSTHORACIC RESECTION; TRANSHIATAL RESECTION; RANDOMIZED-TRIAL; SURGERY; CHEMOTHERAPY; CHEMORADIATION; ADENOCARCINOMA; CISPLATIN;
D O I
10.1245/s10434-009-0862-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Esophageal cancer remains a malignancy with high morbidity and mortality despite improvements to diagnosis, staging, chemotherapy, radiation, and surgery. Neoadjuvant therapy (NT) may improve oncologic outcome in many patients, however the degree to which patients benefit remains unclear. We examined the relationship between pathologic response to NT and magnitude of benefit in patients with esophageal cancer. Using a comprehensive esophageal cancer database, we identified patients who underwent esophagectomy between 1994 and 2008. Pathologic response was denoted as complete (pCR), partial (pPR), and nonresponse (NR). Clinical and pathologic data were compared using Fisher's exact and chi-square when appropriate, while Kaplan-Meier estimates were used for survival analysis. We identified 347 patients who underwent esophagectomy, and 262 (75.5%) were treated with NT. The median age was 66 years (28-86 years) with median follow-up of 20 months (1-177 months). There were 106 (40.5%) patients exhibiting pCR, 95 (36.3%) with pPR, and 61 (23.3%) with NR. The rate of R0 resections was higher amongst pCR (100%) compared with 94.7% in pPR (P = 0.02) and 87.5% in NR (P = 0.0007). There were 15 (14.2%) recurrences in pCR, 22 (23.7%) in pPR, and 17 (28.8%) in NR (P = 0.04). Patients achieving pCR had 5-year disease-free survival (DFS) and overall survival (OS) of 52% and 52%, respectively, compared with 36% and 38% in pPR and 22% and 19% in NR (P < 0.0001, P < 0.0001). Esophageal cancer patients frequently succumb to their disease. However, patients treated with neoadjuvant therapy who achieve pCR have a higher rate of R0 resections, fewer recurrences, and improved 5-year OS and DFS.
引用
收藏
页码:1159 / 1167
页数:9
相关论文
共 38 条
[1]   Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113 [J].
Ajani, Jaffer A. ;
Winter, Kathryn ;
Komaki, Ritsuko ;
Kelsen, David P. ;
Minsky, Bruce D. ;
Liao, Zhongxing ;
Bradley, Jeffrey ;
Fromm, Mitchel ;
Hornback, David ;
Willett, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4551-4556
[2]  
[Anonymous], 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4
[3]  
Bancewicz J, 2002, LANCET, V359, P1727
[4]  
Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
[5]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[6]   Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [J].
Burmeister, BH ;
Smithers, BM ;
Gebski, V ;
Fitzgerald, L ;
Simes, RJ ;
Devitt, P ;
Ackland, S ;
Gotley, DC ;
Joseph, D ;
Millar, J ;
North, J ;
Walpole, ET ;
Denham, JW .
LANCET ONCOLOGY, 2005, 6 (09) :659-668
[7]   Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation [J].
Chirieac, LR ;
Swisher, SG ;
Ajani, JA ;
Komaki, RR ;
Correa, AM ;
Morris, JS ;
Roth, JA ;
Rashid, A ;
Hamilton, SR ;
Wu, TT .
CANCER, 2005, 103 (07) :1347-1355
[8]   A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma [J].
Chu, KM ;
Law, SYK ;
Fok, M ;
Wong, J .
AMERICAN JOURNAL OF SURGERY, 1997, 174 (03) :320-324
[9]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[10]   Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: Pathologic complete response induced by chemotherapy leads to long-term survival [J].
Darnton, SJ ;
Archer, VR ;
Stocken, DD ;
Mulholland, PJ ;
Casson, AG ;
Ferry, DR .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :4009-4015